200,000+ products from a single source!
sales@angenechem.com
132682-98-5 | β-D-Glucopyranose, 1-[N,N'-bis(2-chloroethyl)phosphorodiamidate]
CAS No: 132682-98-5 Catalog No: AG0010ZP MDL No:
Product Description
Catalog Number:
AG0010ZP
Chemical Name:
β-D-Glucopyranose, 1-[N,N'-bis(2-chloroethyl)phosphorodiamidate]
CAS Number:
132682-98-5
IUPAC Name:
(2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
InChI:
InChI=1S/C10H21Cl2N2O7P/c11-1-3-13-22(19,14-4-2-12)21-10-9(18)8(17)7(16)6(5-15)20-10/h6-10,15-18H,1-5H2,(H2,13,14,19)/t6-,7-,8+,9-,10+/m1/s1
InChI Key:
PSVUJBVBCOISSP-SPFKKGSWSA-N
UNII:
1W5N8SZD9A
Properties
Complexity:
369
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
5
Defined Bond Stereocenter Count:
0
Exact Mass:
382.046g/mol
Formal Charge:
0
Heavy Atom Count:
22
Hydrogen Bond Acceptor Count:
9
Hydrogen Bond Donor Count:
6
Isotope Atom Count:
0
Molecular Weight:
383.159g/mol
Monoisotopic Mass:
382.046g/mol
Rotatable Bond Count:
9
Topological Polar Surface Area:
141A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-2
Literature
| Title | Journal |
|---|---|
| Glufosfamide: can we improve the process of anticancer agent development? | Expert opinion on investigational drugs 20120501 |
| Glufosfamide as a new oxazaphosphorine anticancer agent. | Anti-cancer drugs 20110701 |
| A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. | American journal of clinical oncology 20100401 |
| Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. | Cancer chemotherapy and pharmacology 20100101 |
| Induction of DNA breakage in U937 cells by oxazaphosphorines. | Folia biologica 20100101 |
| Possible contribution of beta-glucosidase and caspases in the cytotoxicity of glufosfamide in colon cancer cells. | European journal of pharmacology 20090815 |
| A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. | European journal of cancer (Oxford, England : 1990) 20090601 |
| A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. | Cancer chemotherapy and pharmacology 20080501 |
| A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. | Neoplasia (New York, N.Y.) 20070801 |
| [Identification of glufosfamide metabolites in rats]. | Yao xue xue bao = Acta pharmaceutica Sinica 20060601 |
| Stability of glufosfamide in phosphate buffers and in biological samples. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060307 |
| [Perfect drug targeting. Glufosfamide a new derivative]. | Pharmazie in unserer Zeit 20060101 |
| Glufosfamide: beta-D-Glc-IPM, D 19575. | Drugs in R&D 20050101 |
| Determination of glufosfamide in rat plasma by liquid chromatography/tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20050101 |
| Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. | European journal of cancer (Oxford, England : 1990) 20040301 |
| Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent. | Anticancer research 20040101 |
| European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. | Annals of oncology : official journal of the European Society for Medical Oncology 20031201 |
| Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. | European journal of cancer (Oxford, England : 1990) 20031101 |
| Glufosfamide (Baxter Oncology). | Current opinion in investigational drugs (London, England : 2000) 20021001 |
| Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug beta-D-glucosyl-ifosfamide mustard. | British journal of cancer 20020107 |
| In vitro activity of glufosfamide in childhood acute leukemia. | Anticancer research 20020101 |
| In vitro activity of oxazaphosphorines in childhood acute leukemia: preliminary report. | Acta biochimica Polonica 20020101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.